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Huntington disease (HD) is a fatal neurodegenerative disorder without a cure that is caused by an 
aberrant expansion of CAG repeats in exon 1 of the huntingtin (HTT) gene. Although a negative 
correlation between the number of CAG repeats and the age of disease onset is established, additional 
factors may contribute to the high heterogeneity of the complex manifestation of symptoms 
among patients. This variability is also observed in mouse models, even under controlled genetic 
and environmental conditions. To better understand this phenomenon, we analysed the R6/1 strain 
in search of potential correlates between pathological motor/cognitive phenotypical traits and 
transcriptional alterations. HD-related genes (e.g., Penk, Plk5, Itpka), despite being downregulated 
across the examined brain areas (the prefrontal cortex, striatum, hippocampus and cerebellum), 
exhibited tissue-specific correlations with particular phenotypical traits that were attributable to 
the contribution of the brain region to that trait (e.g., striatum and rotarod performance, cerebellum 
and feet clasping). Focusing on the striatum, we determined that the transcriptional dysregulation 
associated with HD was partially exacerbated in mice that showed poor overall phenotypical scores, 
especially in genes with relevant roles in striatal functioning (e.g., Pde10a, Drd1, Drd2, Ppp1r1b). 
However, we also observed transcripts associated with relatively better outcomes, such as Nfya 
(CCAAT-binding transcription factor NF-Y subunit A) plus others related to neuronal development, 
apoptosis and differentiation. In this study, we demonstrated that altered brain transcription can be 
related to the manifestation of HD-like symptoms in mouse models and that this can be extrapolated to 
the highly heterogeneous population of HD patients.
Huntington’s disease (OMIM #143100) is the most prevalent autosomal dominant polyglutamine (polyQ) dis-
order (5–10 cases per 100,000 inhabitants worldwide), and it is caused by an aberrant expansion of polymorphic 
trinucleotide CAG repeats (>36) in exon 1 of the huntingtin (HTT) gene1. Despite intensive efforts to elucidate 
the etiopathological mechanisms triggered by both the expression of a misfolded mutant HTT fragment (mHtt) 
and the loss of a functional allele, no effective cure is available to patients, who suffer progressive impairments in 
mental and motor functions until death.
To improve and personalize clinical counseling, there is a need for valuable biomarkers to monitor the health 
status of individuals, assess the dosing, efficacy and safety of potential therapeutic approaches and minimize 
uncertainty in clinical decision-making. This is especially relevant in HD, as there is increasing evidence of a 
long-lasting presymptomatic stage with underlying pathological processes2; the number of CAG repeats, although 
inversely correlated with the age of disease onset3,4, is unable to explain the progression and manifestation of 
certain symptoms5–7. In the search for prognostic biomarkers, peripheral blood has been the preferred source8–13. 
Among the strategies for biomarker screening, the exploration of RNA molecules is advantageous because it 
offers a comprehensive and genome-wide repertoire of candidates (both coding and non-coding species) in a 
cost-effective manner. In addition, potential RNA-based markers may be directly linked to the initial stages of 
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disease since transcriptional dysregulation is an early event that occurs prior to cell death, mHtt aggregation and 
mitochondrial dysfunction in cellular preparations and is clearly evident in animal models with minimal phe-
notypical alterations, occurring in both the brain and peripheral tissues14,15. However, the peripheral biomarkers 
that have been proposed thus far have been shown to be substantially inconsistent across the examined human 
cohorts due to a combination of factors16, including those related to the environmental and genetic variability of 
unsupervised human populations as important modulators of the complex HD symptomatology. Thus, intensive 
efforts have focused on identifying genetic modifiers of the age of onset and progression of motor impairment17,18.
To gain insights into the interindividual variations in the manifestation of HD symptoms, the analysis of 
mouse models is pertinent, as these variations can also be observed under controlled environmental condi-
tions and on a controlled genetic background, although expectedly to a much lesser extent than in humans. 
Transcriptional dysregulation is relatively well preserved between mouse and human brains19,20; therefore, the 
resulting candidates may be extrapolated to patients. Previous reports have found correlations between gene 
expression and stages of the disease in both slow and rapidly progressive models of HD21,22, but to our knowledge, 
no study has established this type of correlation on an individual basis. Here, we describe that even slight tran-
scriptional and phenotypical variations can show certain associations in a tissue-dependent manner in environ-
mentally and genetically controlled R6/1 mice.
Results
Phenotypical and transcriptional characterization of the early symptomatic R6/1 strain. To 
expand on the phenotypical characterization of the R6/1 strain on a pure C57/BL6J background, which was ini-
tiated in a previous study23, a battery of behavioural tests was conducted at early symptomatic stages (from 9 to 
13 weeks) to assess the cognitive and motor performances of 24 wild-type and 29 mutant males (see scheme in 
Fig. 1A and Materials and Methods for a detailed description of the animals). Based on previous experiences24, 
we started with cognitive assessments to minimize the impact of the motor component of the pathology on the 
data. In the Morris water maze task (week 9), mutant mice did not show differences compared to their wild-type 
littermates (Fig. 1B–D), but cognitive impairment was more evident in the novel object discrimination (NOD) 
task, in which mutant mice were highly inefficient at remembering familiar objects and both spatial and tempo-
ral changes (Fig. 1E). Although the spontaneous activity of these animals was lower than that of their wild-type 
littermates at week 10 (Fig. 1F,G), reduced thigmotaxis (Fig. 1H) indicated alterations in motivation in addition 
to motor deficits. Motor impairment was clearly evident in the accelerating rotarod task, as mutant mice showed 
shorter latencies and diminished learning capabilities (Fig. 1I). Besides, mutant mice exhibited feet clasping 
(Fig. 1J) and weight loss (Fig. 1K), which both are characteristic of HD mice. These phenotypical traits were 
measured in 11- and 13-week-old animals, showing a trend toward the exacerbation of the differences between 
the genotypes in only two weeks (Fig. 1I–K, compare the Δ values of R6/1 and wild-type mice).
During these experiments, we observed a certain degree of variability among individuals, with a median coef-
ficient of variation (CV) of 45% (interquartile range = 28–59%) and 44% (interquartile range = 32–106%) across 
the tasks for wild-type and mutant mice, respectively. To explore the possible causes of such variability in these 
animals, we obtained samples of the prefrontal cortex, the striatum, the hippocampus and the cerebellum from 
the mice tested on the behavioural battery five days after the last test (week 14) for the sequential isolation of 
total RNA and gDNA. Then, we evaluated the degree of transcriptional dysregulation in the samples by exam-
ining transcripts consistently affected in a variety of brain areas in mouse models of HD: Penk, Plk5, Iptka and 
Rin120,23,24. We confirmed the prominent downregulation of these genes in the four brain areas collected from the 
R6/1 mice compared to their wild-type littermates with RT-qPCR (Fig. 1L), as reported in our previous work. In 
contrast, the expression of a second set of genes related to inflammatory processes and degeneration (Gfap for 
gliosis, H2Q7/8/9 for major histocompatibility complex type Ib, Arg1 for M1 microglial activation and Bax for the 
promotion of apoptosis) was not different between the genotypes in the striatum, the area that is the most sensi-
tive to mHtt expression (Fig. 1M); the exception was Bcl2, which can antagonize the function of Bax25 but which 
role in HD is still under debate26. In conclusion, the R6/1 mice used in this study were significantly impaired at 
the behavioural and transcriptional levels in early stages of the disease without a prominent influence of cell death 
processes.
correlative patterns between phenotype and gene expression. To investigate whether the tran-
scriptional dysregulation of the HD signature was an indicator of the degree of behavioural dysfunction, we 
ranked the animals according to their values obtained for each parameter from less to more affected to estab-
lish potential correlations between phenotypical and transcriptional outcomes using the Spearman’s rank-order 
coefficient (see Materials and Methods for further details). Although we analysed the same deregulated genes 
across the four brain areas, distinctive tissue-specific patterns were observed: meanwhile there was no evident 
correlation between behaviour and gene expression changes in the prefrontal cortex, the changes of Penk, Plk5 
and/or Itpka in the other areas was positively correlated with performance in various tasks: downregulation in 
the striatum was correlated with poor performance in the accelerating rotarod and/or weight loss, downregula-
tion in the hippocampus with poor performance in the NOD task, and downregulation in the cerebellum with 
the severity of feet clasping (Fig. 2A). Certain individuals belonging to the same litters tended to rank similarly, 
suggesting subtle inherited/environmental differences between litters/cohorts that were not entirely controlled in 
our experimental design (Supplementary Fig. S1). In any case, these correlations were not observed in wild-type 
mice. Of note, positive correlations with striatal gene alterations at 11 weeks of age were not evident at 13 weeks, 
closer to the time of sampling; as a result, the progression of motor discoordination and weight loss (calculated as 
the Δ between week 13 and week 11) were negatively correlated with transcriptional dysregulation (“Progress” in 
Fig. 2B). This phenomenon can be tentatively explained by the faster worsening of HD-like phenotypes in animals 
that were initially less affected by mHtt expression at 11 weeks of age, which reduced (but did not abrogate) the 
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Figure 1. Behavioural and gene expression analysis of early symptomatic R6/1 mice. (A) Timeline of the 
behavioural test battery and the sampling of R6/1 mice and their wild-type littermates. MWM, Morris water 
maze; NOD, novel object discrimination. B-D, The Morris water maze task did not reveal differences between 
genotypes in performance in the acquisition phase (B) or in the swimming speed (C) or time spent in the target 
quadrant (TQ) in the probe trials (D). (E) R6/1 mice exhibited significant impairments in the three components 
(“what”, “where” and “when”) of the NOD task. (F–H) Spontaneous activity was measured in the open field test, 
and differences in the speed (F), distance travelled (G) and the time spent in the border area (H) were identified. 
(I) R6/1 animals exhibited significant impairments in the accelerating rotarod task. Motor learning (Δ = day 
2 − day 1) was also affected. (J) R6/1 mice exhibited obvious feet clasping. (K) Mutant mice were unable to gain 
weight, unlike their wild-type littermates. I-K, Progression rates (Δ = week 13 − week 11) for accelerating rotarod 
performance (I), feet clasping (J) and weight gain (K). (L) Genes of a consistent HD transcriptional signature 
(Penk (proenkephalin), Plk5 (polo-like kinase 5), Itpka (inositol trisphosphate 3-kinase A), and Rin1 (Ras and Rab 
interactor 1)) were downregulated in the prefrontal cortex, striatum, hippocampus and cerebellum of R6/1 mice, 
as determined by RT-qPCR assays. (M) Except for Bcl2 (B-cell lymphoma 2), the degeneration-related genes Gfap 
(glial fibrillary acidic protein), H2Q7/8/9 (histocompatibility 2, Q region locus 7/8/9), Arg1 (arginase 1), and Bax 
(Bcl-2-associated X) were not affected. In all the panels: n wt = 24, n R6/1 = 29; *P < 0.05; **P < 0.005 between 
genotypes; Mann Whitney U-test. The data are expressed as whisker-and-box plots.
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behavioural variability between individuals (Fig. 2B). In contrast, the correlations with cerebellar changes were 
more pronounced at the later time point (Fig. 2C), indicating that HD symptoms can develop differently in these 
mutant mice.
These results suggested that alterations in gene expression and phenotype are linked. However, other phenom-
ena, such as the number of CAG repeats and mHtt transgene expression, might be more relevant to behaviour 
and hence more strongly correlated. We focused on the striatum, the main area affected in HD that also shows the 
highest genetic instability of CAG repeats27,28, for our subsequent experiments. After we determined the number 
of repeats in the isolated gDNA of each individual, we observed a slight but significant increase in the number 
of CAG repeats (~10) over the span of the behavioural assays (Fig. 3A). However, this increase was not sufficient 
to have a profound impact on phenotype, as revealed by the absence of a meaningful correlation between the 
number of repeats and impairments in striatal-dependent phenotypes (Fig. 3C). Expression of the transgene was 
the most stable among the genes tested in our study (Fig. 3B), and no correlation with phenotype was observed 
(Fig. 3C). Based on these observations, we found that the level of transcriptional dysregulation of certain genes 
can be associated to the degree of impairment for specific phenotypical traits in the R6/1 strain, without a pro-
found influence of the number of CAG repeats and mHtt transgene expression in defining the interindividual 
variability in the mice of our study.
Transcriptional dysregulation is exacerbated in R6/1 mice with a worse phenotype. To better 
understand the relationship between phenotype and transcription in R6/1 mice, we selected those animals of 
the same age (14 weeks) that were differentially affected by mHtt expression at the behavioural level using an 
independent approach to the correlation analysis. To simplify this approach, we focused on phenotypical traits 
measured three weeks before sample collection to identify the wild-type and mutant animals that deviated the 
most from the average in terms of rotarod performance, duration of feet clasping and weight using Z-scores (see 
Figure 2. Transcriptional and behavioural variabilities in R6/1 mice are mildly correlated in a tissue-dependent 
manner. (A) Summary of the Spearman coefficient values between the analysed phenotypical traits and gene 
expression levels. Significant correlations (~unadjusted P < 0.05; *adjusted P < 0.1, linear regression t-test) were 
observed between striatal gene expression and rotarod and weight, between hippocampal gene expression and 
performance on the NOD task and between cerebellar gene expression and feet clasping in R6/1 mice (n = 29). 
These correlations were not observed in the wild-type animals (n = 24). PT, probe trial; Thigm, thigmotaxis. 
(B) The correlation between striatal Penk transcript variations and performance on the accelerating rotarod 
was reduced at the age of 13 weeks. Left panel, the latency to fall off the rod and Penk expression in mutant mice 
ranked from the highest to the lowest values for each time point; week 11 (d2) and week 13 (d15). Right panel, 
the association between progression rate (week 13 − week 11) and the striatal Penk expression level. (C) The 
correlation between cerebellar Penk transcript variations and feet clasping was increased at the age of 13 weeks. 
The panels are displayed as in B.
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Materials and Methods for further details). The four mice of each genotype with the highest and lowest Z-scores 
were classified as “good” and “poor” performers, respectively (Fig. 4A,B). Mutant mice in these two categories 
did not show differences in the number of CAG repeats or mHtt transgene expression (Fig. 4C) but were prone to 
exacerbate the downregulation of the consistent HD signature analysed in the qRT-PCR assays; this trend was not 
observed in wild-type animals (Fig. 4D).
To obtain a complete picture of the gene expression changes associated with worse phenotype/performance, 
striatal RNA was processed for RNA-seq assays to determine the differential gene expression between “good” 
and “poor” mice of each genotype. Whereas no single differentially expressed gene (DEG) between both types 
of wild-type animals was detected, 233 were upregulated and 121 genes downregulated in the striatum of “poor” 
mutant mice compared to “good” mutant mice (adjusted P-value <0.05). Based on the apparent lack of rele-
vant differences among wild-type mice, we pooled the wild-type datasets to increase the statistical power of 
the pair-wise comparisons for each R6/1 group. Then, we investigated the association between the severity of 
the phenotype and HD transcriptional dysregulation. Compared to mutant mice that exhibited less phenotyp-
ical impairment, mutant mice that showed a worse phenotype were more affected at the level of striatal gene 
expression (Fig. 4E). Compilation of these results defined four sets of striatal genes that were significantly altered 
between R6/1 “poor” and R6/1 “good” mice but also between wild-type animals to ensure that we studied changes 
associated with the HD transcriptional dysregulation (Fig. 4F,G). These sets of genes were: (i) those that were 
more significantly downregulated in R6/1 “poor” animals, which included bona fide HD-related genes, such as the 
proenkephalin Penk, the phosphodiesterase Pde10a, the dopamine receptors Drd1 and Drd2, and the phospho-
rylation regulator DARPP-32 (Ppp1r1b) among other neuronal genes, as evidenced by the Gene Ontology (GO) 
enrichment analysis with the terms “Behaviour & learning”, “Neuropeptide”, and “Potassium transport”; (ii) those 
that were more significantly downregulated in R6/1 “good” animals, which included genes involved in neuronal 
development and apoptosis, such as the bilateral polymicrogyria-associated Adgrg1 (aka Gpr56), the inhibitor of 
cyclin-dependent kinases Cdkn1a (aka p21), the inhibitor of the mTOR signalling pathway Ddit4, the fibroblast 
growth factor receptor Fgfr3, and the schizophrenia and bipolar disorder-associated gene Mdga; (iii) those that 
were more significantly upregulated in R6/1 “poor” animals, which were mainly related to axonogenesis, Ca2+ 
regulation and cell adhesion and included the voltage-calcium sensitive channel Cagna1g, the cadherin Cdh2, the 
Down syndrome adhesion molecule Dscam and the axonal midline guidance gene Slit1; and (iv) those that were 
significantly upregulated in R6/1 “good” mice, such as Nfya, a subunit of the transcription factor NF-Y. All DEGs 
are shown in Supplementary Table 1.
Taking profit of the existing longitudinal transcriptomics study conducted in HD knock-in (KI) mice express-
ing different lengths of polyQ21, we validated the association between the newly defined sets of genes with condi-
tions linked to phenotypical worsening. To this end, we first retrieved the top DEGs in the pair-wise comparisons 
between CAG-expanded strains (Q80, Q92, Q111, Q140 or Q175) and control mice (Q20) at different ages (2, 
6 and 10 months). Then, we calculated the percentage of genes more affected in R6/1 “good” or “poor” mice 
amongst the top DEGs in the same direction of change in the KI striatum. Other sets of genes associated with 
HD transcriptional dysregulation but not significantly different between R6/1 “good” and “poor” mice (thereafter 
referred to as the “rest”) were also included in the analysis for comparative purposes. Regarding downregulated 
genes, both the “rest” and R6/1 “poor” genes showed a progressive increase in the percentage of top DEG in 
strains with longer stretches of CAG repeats (Fig. 4H) and in aged animals (Fig. 4I). However, the relative pres-
ence of “poor” genes amongst the top DEG in KI mice was always superior, suggesting a stronger relationship 
Figure 3. Behavioural variability in R6/1 mice is not attributable to the number of CAG repeats or transgene 
expression in the striatum. (A) Representative electrophoregrams of DNA fragment analysis of a mutant 
mouse from the first cohort (upper panel) and last cohort (lower panel) showing an increase in the number 
of CAG repeats. The sharp yellow peaks are the molecular weight standards. (B) Compared to other genes, 
the expression of the R6/1 transgene in the striatum was relatively stable across the mutant mice. Coeff.
Variation = coefficient of variation (s.d./mean). (C) Summary of the Pearson (r) and Spearman (ρ) coefficient 
values indicating no correlation between phenotypical traits and the number of CAG repeats/transgene 
expression (n R6/1 = 29).
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Figure 4. HD transcriptional dysregulation is exacerbated in a worse pathological phenotype. (A) Summary 
of Z-score calculations for classifying the mice according to their phenotype during weeks 11 and 13: “poor”, 
“good” and “average”. Left panel, the number of phenotypical traits with positive or negative Z-scores for the 
three categories of mice. Right panel, Z-score values represented as the mean ± s.e.m. (B) Accelerating rotarod 
performance (left), feet clasping (middle) and weights (right) across the four groups of animals according to 
genotype (wt, R6/1) and phenotype (good, poor); n = 4 in each group. (C) No difference in the number of 
striatal CAG repeats or mHtt transgene expression between R6/1 “good” and “poor” animals was observed. 
(D) The expression of genes belonging to the HD signature across the four groups of animals. In contrast to 
phenotype, differences were only observed in mutant mice by RT-qPCR. *P < 0.05; **P < 0.005 between “good” 
and “poor” wild-type mice; #P < 0.05; ##<0.005 between “good” and “poor” R6/1 mice; Mann Whitney U-test. 
The data are expressed as the mean ± s.d. E, The number of differentially expressed genes (DEGs) related to the 
wild-type striatum (both downregulated and upregulated) was higher for the R6/1 “poor” striatum compared to 
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with phenotype worsening. In contrast, the downregulated genes in R6/1 “good” mice did not exhibit a pro-
gressive pattern (Fig. 4H,I left panels). The opposite behaviour was observed for upregulated genes; whereas 
the overrepresentation of R6/1 “good” genes were mostly observed in comparisons with older mice or animals 
with the highest number of CAG repeats, the R6/1 “poor” genes showed a transient profile (Fig. 4H,I right pan-
els). The interpretation of the latter result was not straightforward unless we assume that the upregulated R6/1 
“good” genes play a protective role against mHtt expression and are intensively activated in severe stages of the 
disease. In this regard, Nfya mRNA has been reported to be upregulated as part of a homeostatic mechanism for 
restoring the decreased protein levels of NF-Y in HD models29, an observation that we replicated in our R6/1 
colony (Supplementary Fig. S2). The potential relevance of this CCAAT-binding factor to neurodegeneration was 
determined by conditionally knocking out Nfya in forebrain postmitotic neurons30. However, the impact of this 
phenomenon was difficult to discern at the level of known NF-Y target genes such as Hsp90b1 (aka Gpr94) which 
was regulated in the opposite direction in our gene expression analysis, and its promoter retained the capability 
to bind both NF-YA and NF-YB subunits in the R6/1 striatum (Supplementary Fig. S2).
Finally, the retrieval of DEGs in the RNA-seq analysis enabled us to widen the correlative analysis of Fig. 2 by 
including more genes related to worse HD phenotype. However, we only identified a single potential association 
between transcriptional dysregulation and particular symptoms in Gabrd, another gene belonging to the consist-
ent HD signature (Supplementary Fig. S3). Overall, we used an alternative approach to demonstrate that general 
worsening of the HD phenotype partially exacerbated HD-linked transcriptional dysregulation in parallel to a 
putative activation of homeostatic responses. However, this gene expression reprogramming did not necessarily 
explain the outcome of specific phenotypical traits.
Discussion
In this study, we provided initial evidence as a proof of concept regarding putative correlations between tran-
scriptional dysregulation and phenotypical impairment in HD. Pathological phenotypes were not correlated with 
degenerative markers (which were not profoundly altered in R6/1 mice compared to wild-type mice, as revealed 
by RT-qPCR and RNA-seq) or the number of CAG repeats. The latter case was surprising, considering the sig-
nificant expansion of repeats across the duration of this study; however, it can be argued that such expansion is 
not sufficient to deeply influence specific phenotypical traits in the context of an extremely long stretch of CAG 
repeats. Of note, the evaluation of genes that were altered across multiple brain areas (i.e., those that belong to a 
consistent HD signature) revealed the association of tissue-dependent gene expression variations with particular 
pathophenotypical traits. Performance on the accelerating rotarod is known to be linked to striatal function31,32, 
and accordingly, we found correlations between striatal gene expression patterns and latency to fall off the rod. 
We also observed an association between feet clasping and cerebellar gene expression, which is in agreement with 
the manifestation of this trait in several mouse mutants with neurological conditions in which the cerebellum 
is affected by genetic manipulation33–35. The association between hippocampal gene expression and scores on 
the NOD task can be explained by the fact that this paradigm involves spatial learning and recognition mem-
ory, which requires the short-term participation of hippocampal circuitry36. More intriguing is the association 
between the striatum and weight loss. The cause of weight loss in HD patients is unknown, but the most likely 
contributing factors are a combination of hyperactivity of the sympathetic nervous system, energy expenditure 
and hypermetabolism, and swallowing difficulties. Although extensive research has been conducted on the role 
of the hypothalamus37, recent work has identified novel actions of the striatum in the regulation of food intake, 
likely taking part in a motivational mechanism underlying rewarding behaviour and the anticipation of food38. 
Whether this behaviour is sufficiently impaired in HD to explain weight loss remains to be determined. Overall, 
these data indicate that altered gene expression patterns can be helpful in ascribing preferential brain regions 
to phenotypical alterations using advanced cellular fractionation procedures and analytical tools without the 
requirement of housekeeping gene normalization. With the resulting information, it would be feasible to design 
selective therapeutic approaches in mouse models by targeting neural populations that are implicated in particu-
lar symptoms such as chorea and depression-like behaviours, to cite some relevant examples of symptoms that are 
clinically managed in patients.
Such approach will be also useful to better dissect the temporal course of molecular and behavioural events, 
as exemplified by the dysregulation of neuropeptides in HD. Among the correlated genes, Penk is the most well 
known in HD as its downregulation is considered a marker of neuronal dysfunction in the striatum in early stages 
the R6/1 “good” striatum. (F,G) Pair-wise comparisons between R6/1 “poor” and “good” striatal transcriptomes 
identified four types of genes based on the direction of change (downregulated or upregulated) and the group 
of mutants in which they were more altered (“good” or “poor”). Each set of genes is represented by the results 
of GO enrichment analysis (P < 0.1, DAVID), except for the upregulated genes in the R6/1 “good” striatum for 
which no significance was retrieved. The data are expressed as the mean ± s.e.m of log P values across the terms 
in each category. Common, common DEGs to pair-wise comparisons between wild-type and R6/1 “poor” and 
between wild-type and R6/1 “good”; Specific, DEGs only appearing in one comparison; Not changing, DEGs 
between R6/1 “poor” and “good” but not altered between wild-type and R6/1. (H,I) The presence (expressed as 
%) of the four sets of genes identified in (F,G) among the top DEGs between KI HD mice with expanded CAG 
repeats and with non-pathological range number of repeats (Q20) at the indicated ages. Two additional sets of 
genes (genes that are dysregulated in HD but are not different between the R6/1 “poor” striatum and the R6/1 
“good” striatum) were also included (“rest”). The downregulated “poor” genes and upregulated “good” genes 
exhibited the most progressive behaviour compared to that of the other sets, both through analysing the effect of 
the CAG length (H) and age (I) on phenotype worsening.
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of HD39,40. This gene encodes a precursor of enkephalins, which are opioid neuropeptides with neuroprotection 
properties41 that are mainly present in D2R-expressing striatopallidal medium spiny neurons (MSNs) in the indi-
rect pathway of movement. These MSNs are thought to degenerate earlier than those in the direct pathway and 
thus can better explain the onset of chorea due to the inadequate activation of cortical areas42. The expression 
of other neuropeptides, such as Pdyn, which produces dynorphin, β-endorphin and others, and Tac1, which 
produces substance P, neurokinin A and others, were found to be linked to a worse HD phenotype according to 
the RNA-seq analysis. These neuropeptides are more related to D1R-expressing nigrostriatal MSNs in the direct 
pathway, the impairment of which seems to be linked to late-onset motor abnormalities such as akinesia and 
dystonia42.
Nonetheless, the transcription-phenotype association cannot be explained using a simplistic model of exac-
erbation of HD transcriptional dysregulation. Although it is true that the RNA-seq analysis conducted on striatal 
RNA from “good” and “poor” performers showed more pronounced changes in both directions (upregulation and 
downregulation), most of these changes were not correlated with specific HD-like symptoms. This side-by-side 
association seems to be confined to a small subset of genes. Nonetheless, a minor component of the disrupted 
gene expression programme was more significantly altered in R6/1 “good” performers, probably indicating a 
homeostatic program in response to the mHtt insult that is more effectively activated in “good” mutant mice 
than in “poor” mutant mice. Other authors have pinpointed that certain transcriptional alterations compen-
sate for inadequate expression levels of proteins (reviewed in15), including the transcription factor NF-Y (29 and 
Supplementary Fig. S2). In any case, whether these genes represent a new avenue for novel therapeutic approaches 
by promoting/enhancing their activity deserves further investigation.
The cause of transcriptional variations in the R6/1 strain remains to be elucidated. Enrichment analysis of 
transcription factor binding sites identified specific putative regulators of DEGs between R6/1 “poor” and “good” 
mice (Supplementary Fig. S4). These regulators include the following: (i) NF-κB for downregulated genes in 
“poor” performers, which is in agreement with the presence of Nfkb2 (which encodes the p52 subunit) in the list; 
(ii) p53, which targets Cdkn1a and Ddit4, for downregulated genes in “good” performers43; and (iii) the serum 
responsive factor SRF in the upregulated genes in “poor” performers, which is in agreement with the enrichment 
of axonogenesis-related genes in the list and the newly proposed role for this transcription factor in dendritic 
growth44. Considering that these mice are isogenic (although we cannot entirely exclude genetic drifts due to 
the propagation of sporadic mutations, strain contamination, etc., in our colony45, a plausible explanation for 
the differentially affectation of the activities of these transcription factors among R6/1 mice involves epigenetics. 
Epigenetic dysregulation in HD has been extensively documented in previous works46,47 and can occur in early 
stages of the disease20. We speculate that slight environmental differences before isolation in individual cages (in 
utero conditions, endured social hierarchies established in the infancy, maternal care, sporadic changes in the 
germline), together with the inheritance of parental epigenetic patterns, may produce a subtle but significant 
impact on the manifestation of the disease in adulthood that may explain the results of Supplementary Fig. S1.
In humans, the large interindividual variability has likely impeded the identification of appropriate biomark-
ers based on gene expression. In line with these observations, we demonstrated that, even animal models with 
a highly controlled genetic background and controlled environmental factors show certain phenotypical varia-
bilities that are associated with transcriptional variations. Whether these associations can be determined using 
the transcriptional profiles of peripheral tissues/fluids is important for designing novel strategies for biomarker 
screening.
Materials and Methods
Animals and behavioural testing. The transgenic B6.Cg-Tg(HDexon1)61Gpb/J strain (known as R6/1)48 
was maintained on a pure C57BL/6 J background as previously reported23, under a 12-h light/dark cycle with food 
and water provided ad libitum. The transgene was transmitted through males. To reduce potential confounding 
factors from sex, only males were used in the study. Moreover, social hierarchy promotes interindividual dif-
ferences49,50, therefore we isolated the subjects of study two weeks before behavioural testing assuming that the 
impact of social isolation affected uniformly across individuals and might be minimal in the short-term. For all 
behavioural tasks, transgenic mice and their wild-type littermates were analysed following the scheme shown in 
Fig. 1A starting at the age of 9 weeks during the light phase of the light/dark cycle: from 9:00 to 19:00 CET for 
Morris water maze, novel discrimination object and actimetry tasks, and from 9:00 to 13:00 CET for Rotarod and 
feet clasping measurements. Data were collected from three independent cohorts of males spanning a period of 
10 months: 1st cohort, n = 5 (wt) and 7 (R6/1), composed by 2 litters; 2nd cohort, n = 10 (wt) and 10 (R6/1), com-
posed by 4 litters; 3rd cohort, n = 9 (wt) and 12 (R6/1), composed by 6 litters.
Spatial learning and memory were analysed by the Morris water maze, as previously described51 with minor 
modifications. The maze consisted of a round pool of water (0.95 m in diameter) divided into four virtual quad-
rants and surrounded by geometric cues on the walls. The escape platform was 2/3 cm under the water surface and 
was invisible to the mice. The water temperature was ~21 °C. During the acquisition phase, the animals performed 
4 trials/day for 4 consecutive days, starting from each of the four quadrants in quasi random order. During the 
acquisition phase, the platform was located in quadrant 2. The time limit was 60 s/trial with a 10 min intertrial 
interval. If an animal did not reach the platform, it was manually placed on the platform for 10 s. The retention 
phase started the day after the completion of the acquisition phase and consisted of a single trial with no platform. 
A second retention phase was performed 72 hours after the end of the acquisition phase. The time required to 
locate the platform during the acquisition phase and the percentage of time spent in quadrant 2 during the reten-
tion phases were analysed using Smart software (Panlab, Spain).
Spontaneous locomotor activity was assessed by measuring the distance travelled by the mice in an opaque 
rectangular box (22 cm long × 44 cm width × 40 cm high) over 30 min. We also measured the % of time spent in 
the borders of the box (thigmotaxis). The novel object discrimination (NOD) task was carried out as previously 
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described52 with minor modifications. On day 2, for habituation purposes, the animals were exposed to 2 objects 
(a yellow rhombohedron and a red cylinder) located in the centre of the box that were not used again during the 
test. The first sample trial was run on day 3. Each mouse was placed in the centre of the box, which contained 3 
copies of a novel object (blue cylinders) arranged in a triangle-shaped configuration. The animals were allowed to 
explore for 5 min. After a delay of 30 min, the second sample trial was performed with 4 novel objects (red cones) 
arranged in a quadratic-shaped spatial configuration. The animals explored this environment for 5 min and were 
allowed to rest for 30 min. The animals then underwent the test trial with 2 copies of the object from sample 
trial 2 (the recent objects) placed in the same position as in the earlier trial, and two copies of the object from 
sample trial 1 (the familiar objects), one of which was placed in the same position as in the earlier trial (the old 
non-displaced object) and the other of which was placed a new position (the familiar displaced object). Integrated 
episodic memory for “what”, “where” and “when” was analysed as previously described52: “What” was defined as 
the difference in time spent exploring the familiar and recent objects, “where” was defined as the difference in 
time spent exploring the displaced and non-displaced objects and “when” was defined as the difference in the 
time spent exploring the familiar non-displaced and recent non-displaced objects.
The rotarod test was performed with LE8200 equipment (Panlab, Harvard Apparatus). On the first day, the 
animals were minimally habituated until they were able to stay on the rod at a fixed rotational speed of 4 r.p.m 
for > 4 min. To minimize memory consolidation, the mice were trained on the acceleration protocol on the same 
day after a minimum of 1 hour of rest. The acceleration protocol involved an increase of 1 r.p.m. every 8.33 s 
starting at 4 r.p.m (day 1). The latencies to fall off the rod (s) were averaged over four trials. The procedure was 
repeated one day and two weeks later (day 2 and day 15, respectively). The learning score was calculated as the 
difference in the latencies between day 2 and day 1, whereas progression in motor impairment was determined 
by calculating the difference in latencies between day 15 and day 2. Following the rotarod test, feet clasping was 
measured as the time for which the animal clasped its hindpaws while it was suspended by its tail for 5 min. 
Progression rate was calculated as the difference between week 13 (day 15) and 11 (day 1).
The experimental protocols were approved by the Comité de Ética de Experimentación Animal - Órgano 
Habilitado de la Universidad de Cádiz and authorized by the Dirección General de la Producción Agrícola y 
Ganadera de la Junta de Andalucía according to European and regional regulations.
RnA extraction and Rt-qpcR. Five days after the final test, the animals were sacrificed by cervical dislo-
cation, and different brain areas (following the sequence of the cerebellum, hippocampus, striatum and prefrontal 
cortex) were immediately dissected and submerged in RNAlater (ThermoFisher) until processing.
Total RNA was extracted using TRIzol (ThermoFisher) and reverse transcribed into cDNA using the 
RevertAid First-Strand cDNA Synthesis kit (ThermoFisher). qPCR was performed on the Qiagen Rotor-Gene 
Q Detection system using PyroTaq EvaGreen qPCR Mix Plus (Cmb-Bioline). For all kits, the manufactur-
ers’ recommendations were followed. Each independent sample was normalized to the level of Gapdh, as 
this gene was not altered in R6/1 brains20,23. The following primer pair sequences were obtained from previ-
ous works: Gapdh (5′-CATGGACTGTGGTCATGAGCC-3′, 5′-CTTCACCACCATGGAGAAGGC-3′), Penk 
(5′-GGCGTGCACACTGGAATGT-3′, 5′-TCCCAGATTTTGAAAGAAGGCA-3′), Plk5 (5′-CACCTGTGTTTG 
CCTTTCCC-3′, 5′-TTTTGAGGTAAAGGGACAAGGTG-3′), Itpka (5′-TACACTCGGCTTTCGCATTG-3′, 
5′-CAAAGACACGGGTCACTTGCT-3′), Rin1 (5′-GCGGCTGCCAGAAGCTAGT-3′, 5′-CCTGGAACATG 
AGCTCTGAGC-3′), Gabrd (5′-ATTGGAGGTGCTCCTGTGAAT-3′, 5′-CCATGTTTGCCTCTGAGATAT-3′), 
Pde10a (5′-TAACAATGCGAGTTGCTTCC-3′, 5′-CAGCCACTTTTCCACAGTCTC-3′), Nfya (5′-ACAAGGGAC 
GGTCACTGTGAC-3′, 5′-TTTGGATAGCAGGCACAGAGC-3′), Bcl2 (5′-CACACCTGGATCCAGGATAAC-3′, 
5′-GAGAAATCAAACAGAGGTCGCA-3′)20,23,24, Gfap (5′-GGACAACTTTGCACAGGACCTC-3′, 5′-TCCAA 
ATCCACACGAGCCA-3′), H2Q7/8/9 (5′-AGGAGCAGAATTACACATGCCA-3′, 5′-CGCCATGTTGGAGA 
GAGTGTAT-3′)53, Arg1 (5′-TGGCTTGCGAGACGTAGAC-3′, 5′-GCTCAGGTGAATCGGCCTTTT-3′)54, Bax 
(5′-TGAAGACAGGGGCCTTTTTG-3′, 5′-AATTCGCCGGAGACACTCG-3′)55, Scn4b (5′-CATGGTTTAG 
TCCTCTGGCTTGG-3′, 5′-CACGGCCCACCACTGTATTG-3′)56, Tac1 (5′-ATGAAAATCCTCGTGGCCGT-3′, 
5′-GTTCTGCATCGCGCTTCTTT-3′)57, and Mbd2 (5′-CCTTAGCAGTTTTGACTTCAGG-3′, 5′-TGGCAATGT 
TGTGTTCAGGT-3′)58. Other sequences were: Hsp90b1 (5′-GATGATCTCCCCCTCAATGTT-3′, 5′-ATATTCGTGC 
CGAACTCCTTC-3′), Nfyb (5′-GACAGCTACGTGGAGCCTCTG-3′, 5′-AGTCCATCTGTGGCGGAGAC-3′) and 
Trpc4 (5′-TGAGAAGGAAGCCAGAAAGCTTCG-3′, 5′-CCTTAACATTCTCCTCCGTCAAGCC-3′).
DnA extraction and cAG repeat analysis. After the aqueous and organic phases were separated during 
the TRIzol procedure, the latter phase was used to isolate gDNA according to the manufacturer’s instructions. To 
remove any potential guanidine isothiocyanate contamination, the DNA pellet was resuspended in water, treated 
with phenol-chloroform-isoamylic alcohol and precipitated with sodium acetate and ethanol. Conventional PCR 
was performed with 75 ng of gDNA using BioTaq DNA polymerase (Bioline) introducing some modifications 
from other works48,59: 0.8 µM primers, 1.5 mM MgCl2, 2.4 mM dNTP mix and 10% DMSO. The program (1 cycle of 
94 °C for 5 min, 35 cycles of 94 °C for 30 s, 64 °C for 30 s and 72 °C for 2 min, and 1 cycle of 72 °C for 10 min) was run 
on a GeneAmp PCR System 2700. The primers were 5′-FAM-ATGAAGGCCTTCGAGTCCCTCAAGTCCTTC
-3′ and 5′-GGCGGCTGAGGAAGCTGAGGA-3′. Two microliters of each reaction was mixed with 1 µl of for-
mamide and 0.5 µl of a molecular weight standard (Orange DNA size standard, MCLAB) and run on an Abi 
Prism 3100 analyser using NimaPOP-7 polymer (Nimagen). The result of capillary electrophoresis was analysed 
with GeneMapper (Applied Biosystems, ThermoFisher).
Statistical analysis. SPSS software (IBM Statistics), Excel (Microsoft) and R-based stats package were used 
for statistical analysis. Mann-Whitney U tests were performed to compare any phenotypical trait or differential 
gene expression between genotypes. To correlate any phenotypical output with gene expression variation we 
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calculated both the Spearman’s rank-order and Pearson’s coefficients; as they produced similar results, only the 
Spearman’s correlation coefficient is depicted in Fig. 2. A linear regression t-test contrasted whether the corre-
lation coefficient was significantly different from 0, corrected for multiple testing with the Benjamini-Hochberg 
method.
For transcriptomics studies, mice were selected according to the phenotype exhibited at the age of 11 and 13 
weeks using Z-scores ((value − average)/standard deviation). Animals were classified as “good” and “poor” per-
formers based on (i) the number of phenotypical traits with positive and negative scores, respectively (Fig. 4A left 
panel), and (ii) the average value of the score across all the behavioural parameters (Fig. 4A right panel).
RnA-seq and bioinformatics. Striatal RNA from classified mice were individually processed using the 
clean-up protocol of the RNeasy Mini Kit (Qiagen), which also included on-column DNase I treatment. This 
purified RNA was analysed for RIN integrity and values > 8.30 were obtained. DNA libraries were produced for 
mRNA using the TruSeq Stranded mRNA kit (Illumina) and subsequently sequenced using a NextSeq apparatus 
(Illumina) at the facilities of the Unidad de Genómica (Cabimer, Seville, Spain) in a 75-bp paired-end configu-
ration. The resulting reads (31.6 M/sample on average) were mapped onto the mouse genome GRCm38/mm10 
using TopHAT Alignment (v 1.0.1) software. The normalization of read counts and differential expression anal-
ysis was conducted using the DEseq2 package from Bioconductor60. DEGs were filtered with an FDR threshold 
of 0.05 (adjusted P-value). The RNA-seq data can be downloaded from the Gene Expression Omnibus (GEO) 
database using the accession number GSE135057.
For meta-analysis purposes, we employed whole transcriptome RNA-seq data of HD KI mice with different 
numbers of CAG repeats (Q20, Q80, Q92, Q111, Q140, Q175) at different ages (2, 6, 10 months old), as reported 
in the original publication (Supplemental Table 1 from21). After dividing the transcriptomes into bins of equal 
number of genes, we counted the number of genes among the top 684 DEGs compared to the Q20 striatum 
from our resulting lists, namely “R6/1 poor”, “R6/1 good” (defined in Fig. 4F,G) and “rest” (overlapping genes in 
pair-wise comparisons between the R6/1 and wild-type striatum after excluding DEGs between R6/1 “poor” and 
“good” mice).
Other additional bioinformatic tools were: Venny (http://bioinfogp.cnb.csic.es/tools/venny/), for identification 
of overlapping genes between multiple lists of genes; DAVID 6.8 (https://david.ncifcrf.gov/), for overrepresenta-
tion analysis of Gene Ontology (GO) terms related to biological processes; and Pscan (http://159.149.160.88/
pscan/), for overrepresentation analysis of transcription factor binding motifs of the TRANSFAC database.
immunodetection and chip analyses. Western blot and ChIP were performed on brain tissues as previously20. 
We used the following antibodies: NF-YA (sc-10779X, Santa Cruz Biotechnologies), NF-YB (Pab 001, GeneSpin), H3 
(ab176842, Abcam), and HRP-conjugated secondary antibodies (Sigma-Aldrich Química S.A.). Western blot quantifica-
tions were performed using ImageJ software. DNA from pooled mice was immunoprecipitated and quantified by qPCR 
to determine the percentage of immunoprecipitated DNA compared to input DNA using the following primers: Hsp90b1/
Grp94 CCAATbox (5′-CCAATGAACGTAGGCGCATA-3′, 5′-TTCGCTAGAAGCCGGAAGTG-3′), Hspa1a 
CCAAT box (5′-CCATAGCAACAGTGTCACTAGTAGCA-3′, 5′-GGGTTCACTGGAGAGTACGGATT-3′), Rab5b 
CCAAT box (5′-TCACCAACTAGCACAAGTGAGAGACT-3′, 5′-GCTACTTATCCCGTCAATCTTCAAG-3′)30, 
and Hbb-bh1 (5′-GCAAGGTCCAGGGTGAAGAAT-3′, 5′-GGTGTGAGGTATAGAAGCTTGGAGAT-3′)20.
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